<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594801</url>
  </required_header>
  <id_info>
    <org_study_id>CP-PP-003</org_study_id>
    <nct_id>NCT01594801</nct_id>
  </id_info>
  <brief_title>Testing the Effect of the InsuPad Device in Daily Life Conditions</brief_title>
  <official_title>Testing the Effect of the InsuPad Device in Daily Life Conditions - The InsuPad in Daily Life Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insuline Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insuline Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the test protocol for the InsuPad device. The aim of the study is to show economical
      benefit when using the InsuPad device, by testing the effect of the InsuPad device on
      reducing injected insulin dose while keeping the same overall glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 months</time_frame>
    <description>The primary endpoint of the study is to demonstrate the non-inferiority (margin of 0.4%) for overall glycaemic control defined as HbA1c of a treatment regimen applying InsuPad combined with an insulin dose reduction of &gt;10% in the test group compared to the control group not using InsuPad.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <description>compare the Frequency of mild hypoglycaemia events (Blood Glucose &lt; 63 mg/dl or 3. 5 mmol/l) with InsuPad and without InsuPad.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Diabetics Mellitus Type 1</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject continue their routine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects using the InsuPad device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InsuPad</intervention_name>
    <description>Use of the InsuPad for at least 3 times a day.</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 to 75 years (including 18 and 75 years old).

          -  Type 1 or type 2 diabetes mellitus subjects with daily short-acting prandial insulin
             intake of &gt; 60 IU/day.

          -  HbA1c &gt;=6.0% and =&lt; 8%

          -  Use of short-acting prandial insulin analogues with multiple daily injections. The
             analog insulin brands to be used will be either insulin Lispro (Humalog, Liprolog) or
             insulin Aspart (NovoRapid) or insulin Glulisin (Apidra).

          -  Subject agrees to sign consent form before any study-specific tests or procedures are
             to be performed.

          -  Study subject is willing to perform at least 5 blood glucose measurements per day for
             at least 3 months, willing to comply with study procedures and to keep a detailed
             patient log book.

        Exclusion Criteria:

          -  Excessive fibrosis, lipo-hypertrophy or eczema at injection sites.

          -  Known gastro- or enteroparesis.

          -  Unstable chronic disease other than diabetes mellitus (e. g. unstable angina pectoris,
             renal disease) for the last six months before study start.

          -  Severe hypoglycaemic events requiring glucagon injection or glucose infusion within
             the last four weeks prior to study start.

          -  Hypoglycaemia unawareness (Score &gt; 4 in the Hypoglycaemia Awareness Questionnaire)

          -  Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior
             to study start

          -  Any known life-threatening disease

          -  Pregnant women, lactating women or women who intend to become pregnant during the
             observation period

          -  Any other condition or compliance issues that might interfere with study participation
             or results

          -  Subjects with heat sensitivity

          -  Subjects involved in or planned to participate in other studies

          -  Subjects who are incapable of contracting or under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Klausmann/ Dr. Welslau</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabeteszentrum Bad Mergentheim</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ikfe GmbH, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH, Zentrum f체r Klinische Studien</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ikfe GmbH Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum F체r Klinische Studien Neuwied</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ikfe GmbH, Potsdam</name>
      <address>
        <city>Potsdam</city>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Notghi Clinical Trials</name>
      <address>
        <city>Potsdam</city>
        <zip>14471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemein채rztliche Berufsaus체bungs-gemeinschaft Waldfischbach-Burgalben</name>
      <address>
        <city>Waldfischbach-Burgalben</city>
        <zip>67714</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://insuline-medical.com</url>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM</keyword>
  <keyword>insulin</keyword>
  <keyword>injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

